Needle free vaccine delivery company Vaxxas‘s skin patch system is an attractive alternative to vaccine delivery via injection, according to a new study. Published in the journal Vaccine, the study said the company’s high-density microarray patch (HD-MAP) (pictured) was particularly attractive in a pandemic. Its’ use would alleviate the strain on healthcare systems by enabling…
Needle-free vaccine delivery company Vaxxas has announced it was awarded $5.4 million from charitable foundation Wellcome for initial studies and a Phase I clinical trial of a potential second-generation typhoid vaccine delivered using Vaxxas’ technology. In a statement on Thursday, the Brisbane-based clinical-stage company said the project is expected to be completed within two years,…
Biotechnology company Vaxxas in partnership with the Queensland Government, has announced the opening of its global headquarters and state-of-the-art manufacturing facility in Brisbane. The company, which is commercialising a needle-free vaccine patch platform, has opened its custom-built 5,500m² Vaxxas Biomedical Facility to support the scale-up of Vaxxas’ needle-free vaccine technology platform. The company’s high-density microarray…
Brisbane-headquartered Vaxxas, which is commercialising a needle-and-syringe-free technology for vaccine delivery, has announced a new Chief Medical Officer and interim results from a recent Phase 1 trial using its technology to administer a SARS-CoV-2 vaccine candidate. The company used the BIO International Convention in Boston to share news of the appointment of Dr Rochelle Chaiken…
Brisbane-based vaccine delivery technology Vaxxas has announced initiation of a Phase 1 clinical trial for flu shots administered by the company’s high-density microarray patch (HD-MAP.) According to a statement from the company on Friday, the trial will take place at three University of the Sunshine Coast’s clinical research sites – in Brisbane, Morayfield and Sippy…
Needle-free vaccination company Vaxxas has announced completion of a funding round worth $34 million, which it says will help it build production capacity and accelerate its clinical program for a Covid-19 vaccine candidate. Among existing investors in the round were OneVentures and University of Queensland technology transfer organisation Uniquest. “This financing from a strong syndicate…
Vaxxas, a Brisbane-based company attempting to replace the needle and syringe for vaccine deliveries, has announced the first in-human trials for a Covid-19 vaccine candidate using its delivery platform. In a statement on Wednesday, the medtech company said a Phase I clinical study had been initiated, conducted at the University of the Sunshine Coast’s Sippy…
Drug delivery system developer Vaxxas has automated the process it uses for manufacturing its high-density microarray patch (HD-MAP) which administers vaccinations to patients. Working with automation specialist Aim Lab, the Brisbane company needed to speed up the manufacturing process for its micro-array systems that encompass thousands of micro-projections that can be coated with a vaccine…
Syringe-free vaccination technology company Vaxxas is to receive an $8.2 million grant to support the scale up of manufacturing at its Australian manufacturing facility. The Cambridge Massachusetts and Australian company was awarded the second round grant as part of the federal government’s Modern Manufacturing Initiative (MMI) to support manufacture of its skin patch which delivers…
Syringe-free vaccination technology company Vaxxas has announced it will recruit participants for a Phase 1 clinical trials combining its delivery patch and a Covid-19 vaccine.
